Unknown

Dataset Information

0

Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia.

ABSTRACT: The development of drugs able to target BTK, PI3k-delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance to these therapies has already been reported due to non-recurrent changes in oncogenic pathways and genes expression signatures. In this study, we investigated the cooperative role of the BCL2 inhibitor venetoclax and the BRD4 inhibitor JQ1. In particular, we found that JQ1 shows additional activity with venetoclax, in CLL cell lines and in ex vivo isolated primary CD19+ lymphocytes, arguing in favour of combination strategies. Lastly, JQ1 is also effective in venetoclax-resistant CLL cell lines. Together, our findings indicated that the BET inhibitor JQ1 could be a promising therapy in CLL, both as first-line therapy in combination with venetoclax and as second-line therapy, after the emergence of venetoclax-resistant clones.

SUBMITTER: Carra G 

PROVIDER: S-EPMC6991693 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia.

Carrà Giovanna G   Nicoli Paolo P   Lingua Marcello Francesco MF   Maffeo Beatrice B   Cartellà Antonio A   Circosta Paola P   Brancaccio Mara M   Parvis Guido G   Gaidano Valentina V   Guerrasio Angelo A   Saglio Giuseppe G   Taulli Riccardo R   Morotti Alessandro A  

Journal of cellular and molecular medicine 20191210 2

The development of drugs able to target BTK, PI3k-delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance to these therapies has already been reported due to non-recurrent changes in oncogenic pathways and genes expression signatures. In this study, we investigated the cooperative role of the BCL2 inhibitor venetoclax and the BRD4 inhibitor JQ1. In particular, we found that JQ1 shows additional activity with venetoclax, in CLL cell lines a  ...[more]

Similar Datasets

Transcriptomics Inhibition of histone readers bromodomain extra-terminal proteins alleviates scleroderma fibrosis
2022-03-01 | GSE186961 | GEO
Unknown Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation.
| S-EPMC7063807 | biostudies-literature
Unknown Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
| S-EPMC5555835 | biostudies-literature
Transcriptomics Inhibition of bromodomain and extra-terminal (BET) recruitment to chromatin as an effective treatment for mixed lineage leukaemia (MLL)-fusion leukaemia
2011-09-30 | E-MTAB-774 | biostudies-arrayexpress
Unknown Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi).
| S-EPMC6560163 | biostudies-literature
Unknown Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
| S-EPMC4013223 | biostudies-literature
Unknown The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
| S-EPMC5133849 | biostudies-literature
Unknown Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
| S-EPMC4480520 | biostudies-literature
Genomics Inhibition of histone readers bromodomain extra-terminal proteins alleviates scleroderma fibrosis
| PRJNA776895 | ENA
Unknown Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
| S-EPMC10726358 | biostudies-literature